Long-term Study of SEP-363856 Tablets for Adults with Schizophrenia to Evaluate Safety and Tolerability

What this Trial Is About

Researchers are evaluating the safety of a drug called SEP-363856 in adults diagnosed with schizophrenia. The study aims to understand how well patients tolerate the medication when taken daily for up to 52 weeks. This research is a phase 3 trial led by Otsuka Pharmaceutical Co., Ltd., focusing on long-term treatment effects in clinically stable individuals with this condition. Participants will take SEP-363856 tablets once daily, starting with 50 mg per day for the first three days, increasing to 75 mg per day for days four to seven. From day eight onwards, the dose will typically be 100 mg per day unless there are concerns about tolerability, in which case the dose may be adjusted to 75 mg. The study does not include a comparison group and all participants receive the investigational medication. During the 52-week treatment period, researchers will monitor participants closely for any adverse events and measure how often these treatment-emergent side effects occur. Participants will have regular assessments to ensure clinical stability, including evaluations of symptoms and medication adherence. The study provides ongoing safety monitoring throughout the year-long participation.

A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia